Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Rowley

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2020
Reply to: "Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease"Patrick A Lewis, Helene Plun-Favreau, Mark Rowley, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 25, 2020
Pierre D. and the first photographs of Parkinson's diseasePatrick A Lewis, Helene Plun-Favreau, Mark Rowley, et al.
Cancer Medicine|April 25, 2023
Latent heterogeneity of muscle-invasive bladder cancer in patient characteristics and survival: A population-based nation-wide study in the Bladder Cancer Data Base Sweden (BladderBaSe)Christel Häggström, Mark Rowley, Fredrik Liedberg, et al.
Chest|April 9, 2023
ResponseRory A Cameron, Mark Rowley, Nicholas J Simmonds, et al.
International Journal of Cancer|May 11, 2018
Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and Type 2 diabetes mellitusChristel Häggström, Mieke Van Hemelrijck, Hans Garmo, et al.
Chest|July 22, 2022
Treatment Preference Among People With Cystic Fibrosis: The Importance of Reducing Treatment BurdenRory A Cameron, Daniel Office, Jessie Matthews, et al.
BMC Cancer|November 19, 2015
Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysisWahyu Wulaningsih, Mariam Vahdaninia, Mark Rowley, et al.
Oncotarget|September 14, 2016
HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC statusGregory Weitsman, Paul R Barber, Lan K Nguyen, et al.
Journal of the National Cancer Institute|December 19, 2019
HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal TrialPaul R Barber, Gregory Weitsman, Katherine Lawler, et al.
Ebiomedicine|February 20, 2026
Fusing data from CT deep learning, CT radiomics and peripheral blood immune profiles to diagnose lung cancer in a cohort of patients experiencing symptomsRami Mustapha, Balaji Ganeshan, Sam Ellis, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2020
Reply to: "Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease"Patrick A Lewis, Helene Plun-Favreau, Mark Rowley, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 25, 2020
Pierre D. and the first photographs of Parkinson's diseasePatrick A Lewis, Helene Plun-Favreau, Mark Rowley, et al.
Cancer Medicine|April 25, 2023
Latent heterogeneity of muscle-invasive bladder cancer in patient characteristics and survival: A population-based nation-wide study in the Bladder Cancer Data Base Sweden (BladderBaSe)Christel Häggström, Mark Rowley, Fredrik Liedberg, et al.
Chest|April 9, 2023
ResponseRory A Cameron, Mark Rowley, Nicholas J Simmonds, et al.
International Journal of Cancer|May 11, 2018
Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and Type 2 diabetes mellitusChristel Häggström, Mieke Van Hemelrijck, Hans Garmo, et al.
Chest|July 22, 2022
Treatment Preference Among People With Cystic Fibrosis: The Importance of Reducing Treatment BurdenRory A Cameron, Daniel Office, Jessie Matthews, et al.
BMC Cancer|November 19, 2015
Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysisWahyu Wulaningsih, Mariam Vahdaninia, Mark Rowley, et al.
Oncotarget|September 14, 2016
HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC statusGregory Weitsman, Paul R Barber, Lan K Nguyen, et al.
Journal of the National Cancer Institute|December 19, 2019
HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal TrialPaul R Barber, Gregory Weitsman, Katherine Lawler, et al.
Ebiomedicine|February 20, 2026
Fusing data from CT deep learning, CT radiomics and peripheral blood immune profiles to diagnose lung cancer in a cohort of patients experiencing symptomsRami Mustapha, Balaji Ganeshan, Sam Ellis, et al.
Pageof 2